Disease Domain | Count |
---|---|
Nervous System Diseases | 2 |
Endocrinology and Metabolic Disease | 2 |
Top 5 Drug Type | Count |
---|---|
AAV based gene therapy | 5 |
Top 5 Target | Count |
---|---|
ASS(argininosuccinate synthase 1) | 1 |
ATP7B(ATPase copper transporting beta) | 1 |
Target |
Mechanism ATP7B gene stimulants [+1] |
Active Org. ![]() |
Originator Org. ![]() |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Gene transference |
Active Org. |
Originator Org. ![]() |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Gene transference |
Active Org. ![]() |
Originator Org. ![]() |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date03 Sep 2021 |
Sponsor / Collaborator ![]() |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
VTX-801 ( ATP7B ) | Hepatolenticular Degeneration More | Phase 2 Clinical |
VTX-802 | progressive familial intrahepatic cholestasis More | Preclinical |
VTX-803 | Cholestasis, Progressive Familial Intrahepatic 3 More | Preclinical |
VTX-805 | Liver Diseases More | Preclinical |
VTX-804 ( ASS ) | Citrullinemia More | Preclinical |